|
π
|
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
29 auth.
R. Stupp,
S. Taillibert,
A. Kanner,
W. Read,
D. Steinberg,
B. Lhermitte,
S. Toms,
A. Idbaih,
M. Ahluwalia,
K. Fink,
F. Di Meco,
F. Lieberman,
Jay-Jiguang Zhu,
G. Stragliotto,
D. Tran,
...
S. Brem,
A. Hottinger,
E. Kirson,
G. Lavy-Shahaf,
U. Weinberg,
Chae-Yong Kim,
S. Paek,
G. Nicholas,
Jordi Burna,
H. Hirte,
M. Weller,
Y. Palti,
M. Hegi,
Z. Ram
|
10 |
2017 |
10
π
|
|
π
|
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
30 auth.
R. Stupp,
S. Taillibert,
A. Kanner,
S. Kesari,
D. Steinberg,
S. Toms,
L. Taylor,
F. Lieberman,
A. Silvani,
K. Fink,
G. Barnett,
Jay-Jiguang Zhu,
J. Henson,
H. Engelhard,
Thomas C Chen,
...
D. Tran,
J. Ε roubek,
N. Tran,
A. Hottinger,
J. Landolfi,
R. Desai,
M. Caroli,
Y. Kew,
J. Honnorat,
A. Idbaih,
E. Kirson,
U. Weinberg,
Y. Palti,
M. Hegi,
Z. Ram
|
10 |
2015 |
10
π
|
|
π’
|
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
20 auth.
H. Okada,
P. Kalinski,
R. Ueda,
A. Hoji,
G. Kohanbash,
T. Donegan,
A. Mintz,
J. Engh,
D. Bartlett,
C. Brown,
...
H. Zeh,
M. Holtzman,
T. Reinhart,
T. Whiteside,
L. Butterfield,
R. Hamilton,
D. Potter,
I. Pollack,
A. Salazar,
F. Lieberman
|
9 |
2011 |
9
π’
|
|
π
|
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08
33 auth.
P. Wen,
W. Yung,
K. Lamborn,
P. Dahia,
Yanfeng Wang,
B. Peng,
L. Abrey,
J. Raizer,
T. Cloughesy,
K. Fink,
M. Gilbert,
Susan M. Chang,
L. Junck,
D. Schiff,
F. Lieberman,
...
H. Fine,
M. Mehta,
H. Robins,
L. Deangelis,
M. Groves,
V. Puduvalli,
V. Levin,
C. Conrad,
E. Maher,
K. Aldape,
M. Hayes,
L. Letvak,
M. Egorin,
R. Capdeville,
R. Kaplan,
A. Murgo,
C. Stiles,
M. Prados
|
8 |
2006 |
8
π
|
|
π’
|
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
Frederick H Hausheer,
R. Schilsky,
S. Bain,
E. Berghorn,
F. Lieberman
|
8 |
2006 |
8
π’
|
|
π
|
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
39 auth.
I. Vivanco,
H. Robins,
D. Rohle,
Carl Campos,
C. Grommes,
P. Nghiemphu,
Sara P. Kubek,
Barbara Oldrini,
M. Chheda,
Nicolas A. Yannuzzi,
H. Tao,
Shaojun Zhu,
A. Iwanami,
Daisuke Kuga,
Julie H T Dang,
...
Alicia M. Pedraza,
C. Brennan,
A. Heguy,
L. Liau,
F. Lieberman,
W. Yung,
M. Gilbert,
D. Reardon,
J. Drappatz,
P. Wen,
K. Lamborn,
Susan M. Chang,
M. Prados,
H. Fine,
S. Horvath,
N. Wu,
A. Lassman,
L. Deangelis,
W. Yong,
J. Kuhn,
P. Mischel,
M. Mehta,
T. Cloughesy,
I. Mellinghoff
|
8 |
2012 |
8
π
|
|
π
|
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
29 auth.
R. Stupp,
S. Taillibert,
A. Kanner,
W. Read,
D. Steinberg,
B. Lhermitte,
S. Toms,
A. Idbaih,
M. Ahluwalia,
K. Fink,
F. Meco,
F. Lieberman,
Jay-Jiguang Zhu,
G. Stragliotto,
D. Tran,
...
S. Brem,
A. Hottinger,
E. Kirson,
G. Lavy-Shahaf,
U. Weinberg,
Chae-Yong Kim,
S. Paek,
G. Nicholas,
Jordi Burna,
H. Hirte,
M. Weller,
Y. Palti,
M. Hegi,
Z. Ram
|
8 |
2017 |
8
π
|
|
π
|
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
18 auth.
J. Raizer,
L. Abrey,
A. Lassman,
Susan M. Chang,
K. Lamborn,
J. Kuhn,
W. Yung,
M. Gilbert,
K. Aldape,
P. Wen,
...
H. Fine,
M. Mehta,
L. Deangelis,
F. Lieberman,
T. Cloughesy,
H. Robins,
J. Dancey,
M. Prados
|
8 |
2010 |
8
π
|
|
π
|
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
20 auth.
A. Lassman,
M. Rossi,
Jeffrey R. Razier,
L. Abrey,
F. Lieberman,
Chelsea N. Grefe,
K. Lamborn,
W. Pao,
A. Shih,
J. Kuhn,
...
R. Wilson,
N. Nowak,
J. Cowell,
L. Deangelis,
P. Wen,
M. Gilbert,
Susan M. Chang,
W. Yung,
M. Prados,
E. Holland
|
7 |
2005 |
7
π
|
|
π
|
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
17 auth.
John F. de Groot,
K. Lamborn,
Susan M. Chang,
Mark R Gilbert,
T. Cloughesy,
K. Aldape,
Jun Yao,
Edward F. Jackson,
F. Lieberman,
H. Robins,
...
Minesh P. Mehta,
A. Lassman,
L. Deangelis,
W. A. Yung,
A. Chen,
Michael D. Prados,
Patrick Y. Wen
|
7 |
2011 |
7
π
|
|
π
|
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
17 auth.
John F. de Groot,
K. Lamborn,
Susan M. Chang,
Mark R Gilbert,
T. Cloughesy,
K. Aldape,
Jun Yao,
Edward F. Jackson,
F. Lieberman,
H. Robins,
...
Minesh P. Mehta,
A. Lassman,
L. Deangelis,
W. A. Yung,
A. Chen,
Michael D. Prados,
Patrick Y. Wen
|
7 |
2011 |
7
π
|
|
π
|
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
18 auth.
A. Norden,
J. Raizer,
L. Abrey,
K. Lamborn,
A. Lassman,
Susan M. Chang,
W. Yung,
Mark R Gilbert,
Howard A. Fine,
M. Mehta,
...
L. Deangelis,
T. Cloughesy,
H. Robins,
K. Aldape,
J. Dancey,
Michael D. Prados,
F. Lieberman,
P. Wen
|
7 |
2009 |
7
π
|
